Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

导出原文传递

翻译打印收藏纠错

第一作者： Rafal,Dziadziuszko

第一单位： Medical University of Gdansk, Department of Oncology and Radiotherapy, Gdansk, Poland.

作者： Rafal,Dziadziuszko ^[1] ; Egbert F,Smit ^[2] ; Urania,Dafni ^[3] ; Juergen,Wolf ^[4] ; Bartosz,Wasąg ^[5] ; Wojciech,Biernat ^[6] ; Stephen P,Finn ^[7] ; Roswitha,Kammler ^[8] ; Zoi,Tsourti ^[9] ; Manuela,Rabaglio ^[8] ; Barbara,Ruepp ^[8] ; Heidi,Roschitzki-Voser ^[8] ; Rolf A,Stahel ^[10] ; Enriqueta,Felip ^[11] ; Solange,Peters ^[12]

作者单位： Medical University of Gdansk, Department of Oncology and Radiotherapy, Gdansk, Poland. ^[1] VU University Medical Center, Department of Pulmonary Diseases & Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. ^[2] Frontier Science Foundation-Hellas & National and Kapodistrian University of Athens, Athens, Greece. ^[3] University Hospital Cologne, Department of Internal Medicine, Cologne, Germany. ^[4] Medical University of Gdansk, Department of Biology and Genetics, Gdansk, Poland. ^[5] Medical University of Gdansk, Department of Pathology, Gdansk, Poland. ^[6] Cancer Molecular Diagnostics, St. James's Hospital and Trinity College, Dublin, Ireland. ^[7] European Thoracic Oncology Platform (ETOP), Bern, Switzerland. ^[8] Frontier Science Foundation-Hellas, Athens, Greece. ^[9] University Hospital Zurich, Clinic of Oncology, Zurich, Switzerland. ^[10] Vall d'Hebron University Hospital, Institute of Oncology, Barcelona, Spain. ^[11] Centre Hospitalier Universitaire Vaudois (CHUV), Département d'Oncologie, Lausanne, Switzerland. Electronic address: Solange.Peters@chuv.ch. ^[12]

关键词 Afatinib NSCLC erb-b2 receptor tyrosine kinase 2 (HER2) mutations